National cancer institute perspectives.
The National Cancer Institute (NCI) Perspectives this year presented information on the systemic targeted radionuclide therapy (STaRT) research projects: (1) being investigated at the NCI's Intramural Center for Cancer Research; (2) funded by NCI's Radiation Research Program and other extramural programs; and (3) the appropriate National Institutes of Health/NCI funding mechanisms applicable to researchers for obtaining funds for STaRT projects.
Wong
Rosemary S L
RS
Radiation Research Program, Radiotherapy Development Branch, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. rw26f@nih.gov
Brechbiel
Martin W
MW
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D035843:Biomedical Research; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000191:economics*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012109:Research Support as Topic; D000068878:Trastuzumab; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D011994:Recombinant Proteins; D000068878:Trastuzumab